STOCK TITAN

Ascendis Pharma executive sells 20,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Ascendis Pharma A/S reported that its EVP & Chief Admin Officer, Anni Lotte Kirstine Sonderbjerg Pedersen, exercised 20,000 warrants on November 17, 2026, acquiring 20,000 ordinary shares. She then sold 20,000 ordinary shares at $263.886 per share that day. Her warrant balance following the exercise was 0. No Rule 10b5-1 plan is reported.

Insider PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG
Role EVP & Chief Admin Officer
Sold 20,000 shs ($5.28M)
Approx. gross sale proceeds $5.28M
Approx. exercise cost $744K
Approx. pre-tax spread $4.53M
Share of Position Sold 50.7%
Type Security Shares Price Value
Exercise Warrants F1 20,000 $0.00 $0.00
Exercise Ordinary Shares 20,000 $37.18 $744K
Sale Ordinary Shares 20,000 $263.886 $5.28M
Holdings After Transaction: Warrants — 0 warrants (Direct); Ordinary Shares — 19,460 shares (Direct)
Holdings Before and After: Warrants, 20,000 to 0 warrants (Direct); Ordinary Shares, 19,460 to 19,460 shares (Direct)
Footnotes (1)
  1. F1. The warrants are fully vested and exercisable.
Warrants exercised 20,000 warrants November 17, 2026
Exercise price $37.18 per share Warrants exercised on November 17, 2026
Ordinary shares acquired 20,000 shares Through warrant exercise on November 17, 2026
Ordinary shares sold 20,000 shares November 17, 2026
Sale price $263.886 per share Ordinary shares sold on November 17, 2026
Warrants following exercise 0 warrants Following the November 17, 2026 exercise
fully vested and exercisable financial
"The warrants are fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ASND shares did Anni Lotte Kirstine Sonderbjerg Pedersen sell?

She sold 20,000 ordinary shares at $263.886 per share on November 17, 2026.

What was the exercise price for the ASND warrants?

The warrants had a $37.18 per-share exercise price when Anni Lotte Kirstine Sonderbjerg Pedersen exercised them.

Were the ASND warrants vested when exercised?

Yes. The warrants were fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG

(Last)(First)(Middle)
C/O ASCENDIS PHARMA A/S
TUBORG BOULEVARD 12

(Street)
HELLERUPDK-2900

(City)(State)(Zip)

DENMARK

(Country)
2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief Admin Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares11/17/2026M20,000A$37.1839,460D
Ordinary Shares11/17/2026S20,000D$263.88619,460D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants$37.1811/17/2026M20,000 (1)12/12/2027Ordinary Shares20,000$00D
Explanation of Responses:
1. The warrants are fully vested and exercisable.
/s/ Michael Wolff Jensen as attorney-in-fact for Lotte Sonderbjerg11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading